[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point",
    "summary": "Bristol-Myers Squibbâs strong oncology sales and upcoming approvals make its stockâs risk/reward profile increasingly attractive. Read more here on BMY stock here.",
    "url": "https://finnhub.io/api/news?id=e1c9b0b9fdecd0ec7458ae8850bbc3edb9bed3985e2a2c5b877217882f2dabc0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757324865,
      "headline": "Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point",
      "id": 136668842,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227488268/image_1227488268.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibbâs strong oncology sales and upcoming approvals make its stockâs risk/reward profile increasingly attractive. Read more here on BMY stock here.",
      "url": "https://finnhub.io/api/news?id=e1c9b0b9fdecd0ec7458ae8850bbc3edb9bed3985e2a2c5b877217882f2dabc0"
    }
  },
  {
    "ts": null,
    "headline": "Verizon, Merck share losses contribute to Dow's 118-point drop",
    "summary": "Verizon, Merck share losses contribute to Dow's 118-point drop",
    "url": "https://finnhub.io/api/news?id=b7af68cac5c2809cc362ea9c0d7f1aadd91aa495b69ee0d525e3b966d9fdf5df",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757324700,
      "headline": "Verizon, Merck share losses contribute to Dow's 118-point drop",
      "id": 136713848,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Verizon, Merck share losses contribute to Dow's 118-point drop",
      "url": "https://finnhub.io/api/news?id=b7af68cac5c2809cc362ea9c0d7f1aadd91aa495b69ee0d525e3b966d9fdf5df"
    }
  }
]